GLAXOSMITHKLINE PHARMACEUTICALS LTD. Q1 FY27 Results

GlaxoSmithKline Pharmaceuticals delivered a clean double-digit growth quarter. On a consolidated basis — the primary lens, as it strips out intra-group flows — Q1 FY27 revenue rose 16.6% YoY to ₹938 Cr (₹805 Cr) and PAT rose 15.7% to ₹237 Cr (₹205 Cr), with EPS at ₹14.00 versus ₹12.10 a year ago. Both lines were down sequentially (revenue −5.7%, PAT −14.6% off Q4's ₹995 Cr / ₹278 Cr), but Q4 is seasonally the company's strongest quarter and carried a peak ~35% operating margin, so the QoQ dip is a seasonality artifact rather than a slowdown; the YoY read is what matters and it is firmly positive.

The standalone-vs-consolidated gap is the one thing readers must not misread. Standalone PAT of ₹253 Cr is HIGHER than consolidated ₹237 Cr and shows a flattering +23.8% YoY — but that is inflated by an ₹18 Cr dividend from 100%-owned subsidiary Biddle Sawyer sitting in standalone other income (₹61.6 Cr vs ₹43.8 Cr consolidated). That dividend eliminates on consolidation, where the subsidiary instead contributes only its own ₹1.84 Cr profit, so consolidated +15.7% is the true underlying growth. There were no exceptional items in either the current or year-ago quarter, so raw and adjusted growth are the same. On margins, operating margin was ~31.5%, essentially flat versus 31.2% a year ago but well below Q4's ~35.3%; consolidated net margin edged up to 25.3% from 24.2% YoY, helped by a lower effective tax charge. The margin bridge is unremarkable — this was a topline-led quarter, driven by the base business normalising after last year's supply disruptions rather than by cost leverage.

The stock went into the print at ₹2,655, up 10.8% over the past month of trading.

Against the bar we set in our pre-result preview, the print beats on the bottom line and lands mid-range on the top: revenue of ₹938 Cr fell inside the ₹900–950 Cr we expected, PAT growth of ~16% cleared the 6–10% YoY we flagged, but EBITDA margin of ~31.5% undershot the 33–35% band we looked for — a Q4-to-Q1 seasonal give-back, not a structural erosion. There is no public Street consensus for this quarter (coverage is thin; Motilal Oswal's ₹2,170 target frames the specialty thesis but sets no Q1 estimate). Versus management's own framing on the February concall — a long-term ambition to double revenue to ₹8,000 Cr over 5–7 years at 12–14% annual growth — this quarter's 16.6% runs comfortably ahead of that band, supporting the confident tone management carried into FY27; the company gives no formal near-term revenue or margin guidance. Of the watch items we flagged, the ₹3.54 Cr NPPA demand notice (June) is immaterial against a ₹938 Cr topline and did not dent the print; the FY26 annual report/AGM cleared in June with a ₹57/share final dividend. Alongside results the board re-appointed MD Bhushan Akshikar for two years from 1 December 2026, while non-executive director Subesh Williams resigned and Karine Natland (SVP APAC, GSK General Medicines) was named to replace him — continuity at the top with a stronger specialty-strategy link on the board. No management press release accompanied the numbers.

GSK India spent FY26 wrestling with supply disruptions that capped topline growth to 2%, even as profit surged 10% and EBITDA margins expanded 290bps to 34%. The company emerged from that headwind with a clear strategic bet: shift away from slow-growth base generics (topical corticosteroids, anti-infectives) toward oncology, adult vaccines, and specialty medicines—where pricing power and unit growth are both stronger. Management now targets double-digit growth for FY27. Q1 is the litmus test. The question isn't whether new launches will succeed (oncology historically delivers); it's whether the base business has stabilized enough to offset volume softness and whether mix shift can sustain 34% margins.

A strong Q1 would show: Q-o-Q sequential revenue recovery (supply no longer a constraint), new-product uptake in oncology (measurable traction, not just pipeline narrative), and EBITDA margin above 33%. A weak Q1 would signal: flat or negative base-business growth (old portfolio still declining), new launches not yet moved the dial (adoption slower than guided), and margins compressed below 32% (pricing pressure or unfavorable mix).

GSK India enters Q1 FY27 with tailwinds and headwinds. The tailwind: supply now resolved, new oncology/vaccine products in early ramp, and FY26 margin beat establishes a healthy base for margin stability. The headwind: FY26 revenue growth was only 2% (below the pharma mid-single-digit norm), and the base business—which still funds most of cash flow—has faced two years of share loss. To hit the FY27 double-digit guide, Q1 has to show not just that specialty is gaining, but that it's gaining fast enough to more than offset base-business drag. Motilal Oswal (analyst consensus on coverage) expects a 19% EBITDA CAGR over FY25–27 driven by niche launches and market-share gains. Q1 is the first test of that thesis.

Stock at ₹2655.4 (up 27% off 52-week low, down 5% from all-time high). RSI 73.6 signals overbought technicals—room for consolidation or pullback if Q1 misses. Ownership stable: FII 4.62%, DII 7.68%, Promoter 75% (latest Q4 FY26). Volume trend normal. Valuation at 33x earnings sits above historical pharma average; any earnings miss could trigger sharp repricing.